IntegrateRNA Launches Custom Aminoacyl-tRNA In Vitro Synthesis Service to Advance Protein Engineering

IntegrateRNA, the R&D focused business division of Creative Biogene, has launched its Aminoacyl-tRNA In Vitro Synthesis Service to support protein synthesis research by enabling the generation of customized aminoacylated tRNAs. These molecules are essential for robust protein translation in in vitro systems, allowing for more precise and scalable production of proteins containing non-canonical amino acids. The technology provides researchers with tools to engineer proteins with improved functional characteristics, with applications spanning synthetic biology, drug discovery, and enzyme engineering.

The service utilizes a robust in vitro translation system to covalently link amino acids to transfer RNA molecules through an enzyme-based process that mimics natural cellular translation. This approach supports high-yield production of aminoacylated tRNAs and facilitates the inclusion of non-canonical or modified amino acids, expanding the design possibilities for researchers. Scientists can now design and produce custom proteins with enhanced stability, activity, or specificity, potentially leading to new therapeutics or industrial enzymes.

Anticipated applications across pharmaceutical R&D, protein engineering, and novel biologics development include the ability to insert non-standard amino acids into proteins, enabling the creation of protein variants with unique properties not achievable through natural processes alone. Marcia Brady, Head of Technology at Creative Biogene, emphasized that synthesizing proteins with non-canonical amino acids represents a transformative development that opens new possibilities for designing proteins with specific properties and could significantly accelerate biotechnology development.

Future plans for IntegrateRNA include enhancing the Aminoacyl-tRNA synthesis platform to support an even broader array of amino acid modifications and scaling production to industrial levels. These advancements could substantially impact synthetic biology and therapeutic protein development, potentially leading to next-generation biopharmaceuticals and engineered enzymes. The service builds on IntegrateRNA's expertise as a trusted supplier of high-quality oligonucleotides and custom RNA synthesis services, supporting cutting-edge research in molecular biology and therapeutic development across academic, pharmaceutical, and biotechnology sectors.